1 |
2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
|
2 |
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
|
3 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
4 |
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
|
5 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
6 |
Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
|
7 |
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
|
8 |
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
|
9 |
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
|
10 |
Clinical pipeline report, company report or official report of Agenus Lexington
|
11 |
CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy. Acta Pharmacol Sin. 2021 Jan;42(1):142-148.
|
12 |
Clinical pipeline report, company report or official report of EQRx
|
13 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
14 |
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116.
|
15 |
Clinical pipeline report, company report or official report of Akeso Biopharma.
|
16 |
Clinical pipeline report, company report or official report of AstraZeneca
|
17 |
Clinical pipeline report, company report or official report of Jounce Therapeutics.
|
18 |
Clinical pipeline report, company report or official report of MacroGenics
|
19 |
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. N Engl J Med. 2023 May 18;388(20):1853-1862.
|
20 |
Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
|
21 |
Clinical pipeline report, company report or official report of Sanofi
|
22 |
Clinical pipeline report, company report or official report of Xencor
|
23 |
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924.
|
24 |
ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
|
25 |
Clinical pipeline report, company report or official report of 3SBio.
|
26 |
Clinical pipeline report, company report or official report of Novartis.
|
27 |
ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
|
28 |
National Cancer Institute Drug Dictionary (drug id 700595).
|
29 |
Clinical pipeline report, company report or official report of Apollomics.
|
30 |
Clinical pipeline report, company report or official report of Boehringer Ingelheim.
|
31 |
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
|
32 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760).
|
33 |
Clinical pipeline report, company report or official report of Innovent.
|
34 |
A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.
|
35 |
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
|
36 |
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
|
37 |
Clinical pipeline report, company report or official report of Genentech.
|
38 |
Clinical pipeline report, company report or official report of Roche.
|
39 |
Clinical pipeline report, company report or official report of SystImmune.
|
40 |
Clinical pipeline report, company report or official report of Symphogen.
|
41 |
Clinical pipeline report, company report or official report of Xencor.
|
42 |
Clinical pipeline report, company report or official report of Xencor.
|
43 |
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
|
44 |
Clinical pipeline report, company report or official report of Biocytogen
|
|
|
|
|
|
|